Figure 7 This figure compares the progression free survival in response to sunitinib in the SUN
1111 trial ( Raymond et al) with the percent of patients with advanced metastatic PNETs in
response to everolimus in the Radiant 3 trial.(Yao et al ). While the efficacy measures a PFS are
similar the are significant differences in the side effects and choices need to be individualized.